3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
venetoclax
188
Azacitidine
160
Cytarabine
127
fludarabine
96
Cyclophosphamide
74
Specimen Handling
68
fludarabine phosphate
56
Daunorubicin
53
Biopsy
49
Decitabine
47
Whole-Body Irradiation
42
Mycophenolic Acid
40
Idarubicin
40
Busulfan
37
Tacrolimus
35
Injections
35
Granulocyte Colony-Stimulating Factor
35
Melphalan
32
Stem Cell Transplantation
30
gilteritinib
25
Filgrastim
25
CPX-351
25
decitabine and cedazuridine drug combination
23
Peripheral Blood Stem Cell Transplantation
22
Etoposide
20
Mitoxantrone
19
Cladribine
19
ivosidenib
18
Thiotepa
17
Sirolimus
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
bexmarilimab
×
1 year
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled